Statement from Premier Infusion Care (as of 1/3/2022):

Due to the pause in allocation of the EUA monoclonal antibody therapies, including bamlanivimab, etesevimab, and REGEN-COV, Premier Infusion Care is currently suspending our home MAB program until further notice. We will continue to seek updates from the FDA on allocation and efficacy of treatments for Covid-19. Thank you to all of the providers, healthcare partners, and Premier staff that worked diligently to make an impact in the lives of our communities by providing MAB treatment to hundreds of individuals throughout Southern California. Please review the link below for additional information:

https://www.phe.gov/emergency/events/COVID19/therapeutics/update-23Dec2021/Pages/default.aspx